Table 1 Comparison of CPA patients with and without bacterial co-infection

Male gender

79

15 (72)

64 (80)

0.388

Age (year)

57 ± 13 (28–80)

57 ± 12

57 ± 16

0.939

Ever smoking rate

69

16 (80)

53 (75)

0.772

Smoking load (pack/year)

37 ± 20 (5-110)

35 ± 16

45 ± 30

0.087

Symptoms at presentation

Dyspnea

56

15 (71)

41 (51)

0.139

Cough

57

14 (67)

43 (54)

0.331

Hemoptysis

56

10 (48)

46 (58)

0.466

Sputum

17

8 (38)

9 (11)

0.007

Weight loss

7

3 (14)

4 (5)

0.155

Amount of hemoptysis

Bloody-streaked

33

5 (24)

28 (35)

Tea-spoon or table-spoon

15

3 (14)

12 (15)

0.809

Cup

8

2 (10)

6 (8)

Respiratory failure

7

5 (24)

2 (3)

0.007

Any additional diseases

90

18 (86)

72 (90)

0.694

ICU admission

4

2 (10)

2 (3)

0.19

Systemic steroid use

10

5 (24)

5 (6)

0.03

COPD

33

6 (29)

27 (34)

0.796

CAD

5

1 (5)

4 (5)

NS

Asthma

3

-

3 (4)

NS

Bronchiectasis

8

3 (14)

5 (6)

0.358

DM

24

4 (19)

20 (25)

0.755

Malignancy

17

3 (14)

14 (18)

NS

Emphysema

11

4 (19)

7 (9)

0.233

TB Sequela

46

6 (29)

40 (50)

0.091

ILD

8

3 (14)

18 (86)

0.358

CTD

5

1 (5)

4 (5)

NS

Any organ transplant

2

-

2

NS

Pleural effusion

7

1 (5)

6 (8)

NS

Side of involvement

Right

45

10 (48)

35 (44)

Left

37

7 (33)

30 (38)

0.934

Bilateral

19

4 (19)

15 (19)

Lobar involvement

RUL

37

8 (38)

29 (36)

LUL

31

4 (19)

27 (34)

0.162

LLL

3

2 (10)

1 (1)

Multiple lobes

30

7 (33)

23 (29)

TTNAB

6

0

6 (8%)

0.34

Bronchoscopy

75

17 (81)

58 (72)

0.054

Daignosis method

Laboratory

14

3 (14)

11 (14)

Radiology and clinical

14

7 (33)

7 (9)

0.013

Pathology

73

11 (53)

62 (77)

Pathological diagnosis via

TTNA

4

19 (24)

Surgical

47

4 (19)

4 (5)

0.017

Bronchoscopic biopsy

6

1 (5)

43 (54)

Bronchocopic lavage

15

6 (29)

9 (11)

Radiological classification

Simple aspergilloma

43

7 (33)

36 (45)

CCPA

26

5 (24)

21 (26)

CFPA

5

3 (14)

2 (3)

0.198

SAIA

9

2 (10)

7 (9)

Aspergillosis nodule

8

3 (14)

5 (6)

Endobronchial aspergillosis

10

1 (5)

9 (11)

Galactomannan serum

56

10

46

0.715

High levels (> 1)

13

3

10

Galactomannan level

0.867 ± 1.36 (0.015–6.18)

0.949 ± 1.47

0.849 ± 1.35

0.835

Galactomannan BAL

18

3

15

0.685

High (> 1)

17

3

14

Galactomannan level (BAL)

4.926 ± 4.63

2.8 ± 0.5

5.3 ± 4.9

0.401

(0.431–15.225)

Treatment Method

Follow-up

8

3 (14)

5 (6)

Surgery alone

34

4 (19)

30 (38)

0.047

Antifungal Treatment alone

42

13 (62)

29 (36)

Treatment and surgery

17

1 (5)

16 (20)

Antifungal treatment

Fluconazole

1

1

Voriconazole

50

13 (62)

37

0.864

Capofungin

1

1

Itraconazol

7

1 (5)

6

Antifungal treatment complication

9

2 (10)

7 (16)

NS

Surgical operation

51

5

46

0.357

Number of hospitalisation

1–2

93

19 (90)

74 (93)

0.67

3 and more

8

2 (10)

6 (7)

Follow-up duration (months)

27 ± 22 (0–83)

25.7 ± 20.6

28.8 ± 25

0.564

Survival duration (months)

37 ± 25 (0–83)

35.1 ± 27

37.2 ± 23

0.736

Mortality

29

9 (43%)

20 (25%)

0.174

Malignancy

9